Understanding the Impact of New Developments at FDA on the IP Due Diligence Review Process

November 10, 2020 10:45am

Kurt R. Karst
Director
Hyman, Phelps & McNamara PC (Washington, DC)

Mercedes Meyer
Partner
Drinker, Biddle & Reath LLP (Washington, DC)

This panel of FDA experts will discuss:

  • A survey of key laws and regulatory exclusivities that attorneys need to be most aware of when doing IP due diligence on a deal
  • Understanding how the latest developments with patent term extensions are impacting IP due diligence decisions
  • Examining changes made to the BPCIA (Biologics Price Competition and Innovation Act) that impact considerations during the due diligence process
  • Assessing the latest activity surrounding the CREATES Act and the future implications on IP-related deals